TLDR
- Olema Pharmaceuticals (OLMA) fell 41% Monday after Roche’s Phase 3 giredestrant trial failed to hit its primary endpoint
- Roche’s persevERA study found no statistically significant improvement in progression-free survival
- Roche stock dropped as much as 7.5% on the news
- Olema’s own drug, palazestrant, is still in Phase 3 trials with results not expected until 2028
- Stifel analysts said the sell-off could be a buying opportunity for believers in palazestrant’s potential
Olema Pharmaceuticals (OLMA) fell sharply on Monday after Roche reported a late-stage breast cancer drug trial failed. The drop was steep — 41% — and came despite Olema running a completely separate drug program.
Olema Pharmaceuticals, Inc., OLMA
Roche’s Phase 3 persevERA study tested giredestrant combined with palbociclib against an aromatase inhibitor plus palbociclib. The trial did not meet its primary endpoint of a statistically significant improvement in progression-free survival.
Roche said a numerical improvement was seen in the trial. But it wasn’t enough to reach statistical significance — the bar required to declare a drug effective in a clinical trial.
Roche stock dropped as much as 7.5% on the news. That was the stock’s worst single-day drop in over 11 months.
The market reaction spilled over to Olema because the two companies are working in the same space — first-line metastatic breast cancer. Investors linked the Roche failure to Olema’s prospects, even though the drugs are different.
Olema is developing palazestrant, an oral selective estrogen receptor degrader (SERD). The drug is in multiple Phase 3 trials targeting breast cancer.
The most closely watched study, OPERA-02, is testing palazestrant in first-line metastatic breast cancer. Results from that study are not expected until 2028.
What Stifel Said
Stifel analysts pushed back on the sell-off. They noted that while the Roche outcome isn’t ideal for OLMA in the short term, the numerical improvement Roche did see leaves room for palazestrant to be a clinical differentiator.
Stifel pointed to palazestrant’s superior antagonism and pharmacokinetic profile as reasons the drug could perform better than giredestrant in the same setting.
The firm suggested that investors who believe in palazestrant’s best-in-class potential “may see today’s sell-off as a buying opportunity.” The reasoning: if giredestrant can’t get it done, the door is open for palazestrant to be the first major mover in the first-line metastatic breast cancer space.
The Setup for OLMA
Palazestrant has shown early promise in Phase 1 and Phase 2 data. The company has leaned into the drug as a potential best-in-class SERD, arguing its pharmacokinetics set it apart from rivals.
The OPERA-02 trial will be the definitive test. But that readout is still roughly two years away, leaving plenty of uncertainty in the near term.
Giredestrant failing to hit statistical significance doesn’t automatically mean palazestrant will succeed. The two drugs work differently, and the persevERA data doesn’t predict OPERA-02 outcomes.
OLMA stock was down 41% in Monday trading, with the stock reacting to the broader negative sentiment in the oral SERD space following the Roche announcement.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
